Health · 5 views
Novel Drug Doubles PFS in Heavily Pretreated, HR-Positive Breast Cancer
(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized…
Summary
(MedPage Today) -- Patients with heavily pretreated hormone receptor (HR)-positive breast cancer lived twice as long without disease progression with the novel antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren), a randomized trial
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Five ways to look after yourself as winter approachesContinue reading
- Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancerContinue reading
- NHS consultants to go on two-day strike in England in November, says BMAContinue reading
- A virus that afflicts cows makes the jump to a humanContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow